Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
Nat Rev Clin Oncol
    March 2024
  1. KONTOS D
    The promise of AI in personalized breast cancer screening: are we there yet?
    Nat Rev Clin Oncol. 2024 Mar 12. doi: 10.1038/s41571-024-00877.
    >> Share

    January 2024
  2. MARRA A, Chandarlapaty S, Modi S
    Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.
    Nat Rev Clin Oncol. 2024 Jan 8. doi: 10.1038/s41571-023-00849.
    >> Share

    December 2023
  3. BERTON GIACHETTI PPM, Curigliano G
    Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
    Nat Rev Clin Oncol. 2023 Dec 19. doi: 10.1038/s41571-023-00854.
    >> Share

  4. MORRISON L, Loibl S, Turner NC
    The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment.
    Nat Rev Clin Oncol. 2023 Dec 11. doi: 10.1038/s41571-023-00840.
    >> Share

    November 2023
  5. SIDAWAY P
    Sacituzumab govitecan improves OS in heavily pretreated patients.
    Nat Rev Clin Oncol. 2023;20:734.
    >> Share

    October 2023
  6. ARECCO L, Lambertini M
    Safety of interrupting adjuvant endocrine therapy to conceive: early data are POSITIVE.
    Nat Rev Clin Oncol. 2023;20:662-663.
    >> Share

    July 2023
  7. SIDAWAY P
    T-DXd is effective after T-DM1.
    Nat Rev Clin Oncol. 2023;20:426.
    >> Share

    February 2023
  8. O'LEARY B
    PADA-1 trial: ESR1 mutations in plasma ctDNA guide treatment switching.
    Nat Rev Clin Oncol. 2023;20:67-68.
    >> Share

    October 2022
  9. AGOSTINETTO E, Gligorov J, Piccart M
    Systemic therapy for early-stage breast cancer: learning from the past to build the future.
    Nat Rev Clin Oncol. 2022 Oct 17. pii: 10.1038/s41571-022-00687.
    >> Share

    July 2022
  10. VASAN N, Cantley LC
    At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy.
    Nat Rev Clin Oncol. 2022;19:471-485.
    >> Share

    April 2022
  11. SIDAWAY P
    Pembrolizumab improves EFS in TNBC.
    Nat Rev Clin Oncol. 2022;19:220.
    >> Share

    March 2022
  12. SOUTHEY MC, Dugue PA
    Improving breast cancer risk prediction with epigenetic risk factors.
    Nat Rev Clin Oncol. 2022 Mar 29. pii: 10.1038/s41571-022-00622.
    >> Share

    November 2021
  13. BIANCHINI G, De Angelis C, Licata L, Gianni L, et al
    Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.
    Nat Rev Clin Oncol. 2021 Nov 9. pii: 10.1038/s41571-021-00565.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016